Corlanor (Ivabradine Oral Solution) and Xenleta (Lefamulin Tablets)
Determining the interaction of Corlanor (Ivabradine Oral Solution) and Xenleta (Lefamulin Tablets) and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.GENERALLY AVOID: Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ivabradine, which is primarily metabolized by the isoenzyme. According to the product labeling, administration of ivabradine with moderate CYP450 3A4 inhibitors (e.g., diltiazem, verapamil, grapefruit juice) has been shown to increase ivabradine systemic exposure (AUC) by approximately 2- to 3-fold. Elevated plasma levels of ivabradine may increase the risk of excessive bradycardia and conduction disturbances. GENERALLY AVOID: Due to its bradycardic effects, the risk of QT prolongation and torsade de pointes arrhythmia may be increased when ivabradine is used with drugs that can prolong the QT interval. In clinical studies, the rate of bradycardia was 6.0% versus 1.3% per patient-year for ivabradine compared to placebo. At recommended dosages of ivabradine, heart rate reduction is approximately 10 beats per minute at rest and during exercise. In general, the risk of an individual agent or a combination of agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances (e.g., hypokalemia, hypomagnesemia). In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s). MANAGEMENT: Concomitant use of ivabradine with moderate CYP450 3A4 inhibitors that can also prolong the QT interval such as crizotinib, dronedarone, fluconazole, lefamulin (when administered orally), and mifepristone should generally be avoided. If coadministration is required, a dosage reduction of ivabradine should be considered. Some authorities recommend initiating ivabradine at a dosage of 2.5 mg twice daily when used with moderate CYP450 3A4 inhibitors, provided the resting heart rate is at or above 70 beats per minute and frequent cardiac monitoring is performed. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. References Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67
Professional:GENERALLY AVOID: Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ivabradine, which is primarily metabolized by the isoenzyme. According to the product labeling, administration of ivabradine with moderate CYP450 3A4 inhibitors (e.g., diltiazem, verapamil, grapefruit juice) has been shown to increase ivabradine systemic exposure (AUC) by approximately 2- to 3-fold. Elevated plasma levels of ivabradine may increase the risk of excessive bradycardia and conduction disturbances.
GENERALLY AVOID: Due to its bradycardic effects, the risk of QT prolongation and torsade de pointes arrhythmia may be increased when ivabradine is used with drugs that can prolong the QT interval. In clinical studies, the rate of bradycardia was 6.0% versus 1.3% per patient-year for ivabradine compared to placebo. At recommended dosages of ivabradine, heart rate reduction is approximately 10 beats per minute at rest and during exercise. In general, the risk of an individual agent or a combination of agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances (e.g., hypokalemia, hypomagnesemia). In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).
MANAGEMENT: Concomitant use of ivabradine with moderate CYP450 3A4 inhibitors that can also prolong the QT interval such as crizotinib, dronedarone, fluconazole, lefamulin (when administered orally), and mifepristone should generally be avoided. If coadministration is required, a dosage reduction of ivabradine should be considered. Some authorities recommend initiating ivabradine at a dosage of 2.5 mg twice daily when used with moderate CYP450 3A4 inhibitors, provided the resting heart rate is at or above 70 beats per minute and frequent cardiac monitoring is performed. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.
- Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67
Generic Name: ivabradine
Brand name: Corlanor
Synonyms: Corlanor
Generic Name: lefamulin
Brand name: Xenleta
Synonyms: Xenleta (Lefamulin Injection), Xenleta, Xenleta (oral/injection)
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Corlanor (Ivabradine Oral Solution)-Xeomin
- Corlanor (Ivabradine Oral Solution)-Xerava
- Corlanor (Ivabradine Oral Solution)-Xerese
- Corlanor (Ivabradine Oral Solution)-Xerese Cream
- Corlanor (Ivabradine Oral Solution)-Xermelo
- Corlanor (Ivabradine Oral Solution)-Xgeva
- Xenleta (Lefamulin Tablets)-Corlanor (Ivabradine Tablets)
- Xenleta (Lefamulin Tablets)-Corlopam
- Xenleta (Lefamulin Tablets)-Cormax
- Xenleta (Lefamulin Tablets)-Cormax Cream
- Xenleta (Lefamulin Tablets)-Cormax Scalp Application
- Xenleta (Lefamulin Tablets)-Cormax Solution